This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): VX-385, GW640385
Description: Brecanavir is an orally active aspartyl protease inhibitor.
Deal Structure: In December 1993, Vertex and Wellcome signed an agreement to collaborate on the development of novel, orally active protease inhibitors for the treatment of HIV infection and AIDS. Under the terms of the agreement, Wellcome will make payments to Vertex up to $42 million, including an initial payment of $15 million as well as research support and payments for agreed development milestones. Wellcome will also fund all development activities at both companies including any clinical trials which maybe undertaken. Vertex and Wellcome will jointly develop Vertex's HIV protease inhibitors. The companies will also undertake a joint 5-year research program to design and develop other HIV protease inhibitors. Wellcome will receive exclusive rights to develop, manufacture and market Vertex's HIV protease inhibitors in the United States, Europe and other countries outside the Far East. Vertex will receive a substantial royalty on Wellcome sales of products emerging from the program and will...See full deal structure in Biomedtracker
Partners: Vertex Pharmaceuticals Incorporated
Pink Sheet ICAAC In Brief
Additional information available to subscribers only: